Friday, 16 October 2026European Markets

AUGROS COSMETICS Stock Went Up By Over 15% In The Last 5 Sessions

Loading stream...

augros cosmetics of france, a company well known for providing customized packaging solutions, has recently experienced a significant surge in its stock market performance. over a period of five trading sessions, they have seen a remarkable 15.56% increase going from eur6.75 to eur7.80 as of last monday. this impressive upturn is in stark contrast to the declining trend in france's cac 40 index which experienced a drop of 1.26% to eur7,340.19.

augros cosmetic overview

as a provider of decorative solutions to perfumers, cosmeticists, and spirits producers, augros cosmetic stands out with its unique offerings in packaging materials, which include glass, plastic and aluminum. the recent and significant growth of the company indicates a potential upturn in the midst of an otherwise underperforming wider market.

financial performance

financially speaking, augros has shown considerable solidity. they boast an earnings per share (eps) figure of eur0.43, and currently, their price to earnings ratio stands at 18.14. this signifies that investors are spending 1814 euros to acquire one share in augros for every euro earned annually by the company.

investor attraction

the shares of augros cosmetics are retaining their attractiveness even in an unstable market. this is largely due to their consistent earnings, as evidenced by impressive earnings per share and an attractive p/e ratio. these indicators suggest that investors are predicting further growth in the future.

investor advice

investors are strongly recommended to keep a close eye on augros cosmetics's stock. it is crucial to monitor both its performance and any strategic moves or announcements made by the company. currently, the company appears to be defying market trends by pushing its shares in the opposite direction.

more news about augros cosmetics (augr.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com